Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Shares of Insulet Corp. PODD slid 1.90% to $282.80 Friday, on what proved to be an all-around dismal trading session for the ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

Reports Q4 revenue $597.5M, consensus $582.02M. “We concluded an incredible year with a very strong fourth quarter, achieving significant ...

Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth.

Stifel Nicolaus analyst Mathew Blackman maintained a Hold rating on Insulet (PODD – Research Report) today and set a price target of $293.00.

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Van ECK Associates Corp lessened its stake in Insulet Co. (NASDAQ:PODD – Free Report) by 2.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission.

CIBC Asset Management Inc increased its position in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 4.7% in the 4th ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...